Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-06-04, Stock:LLY, The news for the past five days is as follows:
2020-05-28: NEWS1: Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease.NEWS2: U.S. FDA approves Eli Lilly's diagnostic agent for Alzheimer's disease.NEWS3: Thursday Morning Market Highlights.NEWS4: 3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020.
2020-05-29: NEWS1: FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid.NEWS2: Lilly Cleared by FDA to Market Alzheimer's Detection Drug.NEWS3: Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN.NEWS4: Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates.NEWS5: Lilly gets FDA approval for Alzheimer's diagnostic agent.NEWS6: Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent.
2020-06-01: NEWS1: Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today.NEWS2: Coronavirus update: NJ eyes next reopen phase; protests, curfews fan fears of COVID spread.NEWS3: Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'.NEWS4: Coronavirus latest: Monday, June 1.NEWS5: 3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity.NEWS6: A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’.NEWS7: Top Stock Picks for Week of June 1, 2020.NEWS8: Coronavirus update: Global case tally tops 6 million as weekend protests spark concerns they will lead to an increase in infections.NEWS9: Eli Lilly Is Already Testing a COVID-19 Antibody Treatment in Humans.NEWS10: Gilead's stock falls on remdesivir, Eli Lilly begins human study of possible COVID-19 treatment.NEWS11: Dow Jones Erases 150-Point Loss Amid Rising U.S.-China Tensions; Pfizer Dives 8%, But Tesla Surges 6% To Breakout.NEWS12: Gold Little Changed Near $1,750 as U.S. Protests Square off with Reopenings.NEWS13: Eli Lilly Shares Jump After Healthcare Group Doses First Patients in COVID-19 Vaccine Trial.NEWS14: Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer.NEWS15: Cooper Companies (COO) to Post Q2 Earnings: What's in Store?.NEWS16: Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment.NEWS17: Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial.NEWS18: Eli Lilly starts human study of potential COVID-19 antibody treatment.NEWS19: Eli Lilly starts human study of potential COVID-19 treatment.NEWS20: Lilly initiates Phase 1 clinical trial for a COVID-19 antibody treatment.NEWS21: Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA).NEWS22: Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans.
2020-06-02: NEWS1: Coronavirus latest: Tuesday, June 2.NEWS2: These 2 charts show why record-high stock valuations shouldn’t worry investors.NEWS3: Lilly Begins Coronavirus Study to Evaluate Antibody Therapy.NEWS4: Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates.NEWS5: AstraZeneca Ranked Most Inventive, Roche Most Innovative.NEWS6: Morning Bell With Jim Cramer: Buy Regeneron.NEWS7: NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4.NEWS8: Buy Lilly, AbbVie and Merck Stocks, J.P. Morgan Says, but Pfizer Is Still Expensive.NEWS9: Don’t Only Bet on Fast Vaccines, Root for Covid Treatments.NEWS10: Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions.
2020-06-03: NEWS1: How Are Biotech ETFs Reacting to Coronavirus Treatment News?.NEWS2: Wednesday Morning Market Highlights.NEWS3: Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study.NEWS4: Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market.NEWS5: HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates.NEWS6: EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus.NEWS7: EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis.NEWS8: Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate.

Answer: Decrease